Judd W. Moul, MD, urologic oncologist, Duke Medicine, discusses challenges with sequencing therapies for prostate cancer.

The biggest challenge faced, Moul explains, often occurs when a patient has metastatic castration-resistant prostate cancer. Often, Moul starts a treatment plan with sipuleucel-T (Provenge); however, it is unclear whether patients should subsequently receive enzalutamide (Xtandi) or abiraterone acetate (Zytiga).

Both are novel, hormonal therapeutic agents that urologists should be comfortable prescribing to patients. Treatment should be individualized to each patient, Moul adds.

Videos

Judd W. Moul, MD, urologic oncologist, Duke Medicine, discusses challenges with sequencing therapies for prostate cancer. 


Dr. Moul on Challenges With Sequencing Therapies for Prostate Cancer

Judd W. Moul, MD, director, Duke Prostate Center, James H. Semans, MD, Professor of Surgery, Duke University Medical Center, discusses the 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelix.

Moul says the study originally compared degarelix to leuprolide to treat men with advanced prostate cancer. Initial results showed that monthly degarelix and monthly leuprolide were equivalent over the first year. However degarelix did better at lowering testosterone levels quickly in the first two months than leuprolide, Moul says.

Now it has been discovered that there are long-term benefits to treating patients with degarelix compared to leuprolide. The disease-free survival appears to be better with degarelix versus leuprolide, Moul says. 

Judd W. Moul, MD, director, Duke Prostate Center, James H. Semans, MD, Professor of Surgery, Duke University Medical Center, discusses the 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelix

Judd W. Moul, MD

Articles

Dr. Moul on Challenges With Sequencing Therapies for Prostate Cancer

Dr. Moul Discusses the Long-Term Tolerability and Efficacy of Degarelix